Related Experiment Video

Updated: Sep 20, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Resistance to targeted therapies: delving into FLT3 and IDH

Sai Prasad Desikan1, Naval Daver1, Courtney DiNardo1

  • 1Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA.

Blood Cancer Journal
|June 10, 2022
PubMed

Insights

Targeted therapies for FLT3 and IDH mutations in leukemia show promise, but drug resistance remains a challenge. This review covers leukemogenesis, inhibitors, resistance mechanisms, and strategies to overcome them.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Mutations in FLT3 (FMS-like tyrosine kinase 3) and IDH (isocitrate dehydrogenase) are common drivers in acute myeloid leukemia.
  • Targeted inhibitors against FLT3 and IDH have demonstrated significant clinical benefits, improving outcomes for patients with these mutations.

Purpose of the Study:

  • To review the role of FLT3 and IDH in leukemogenesis.
  • To discuss current targeted inhibitors for FLT3 and IDH mutations.
  • To summarize emerging mechanisms of therapeutic resistance and ongoing strategies to overcome them.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of genetic alterations and signaling pathways involved in resistance.
  • Synthesis of data on therapeutic strategies and clinical trial outcomes.

Main Results:

  • FLT3 and IDH targeted therapies have improved response rates and survival.
  • Resistance mechanisms include on-target mutations, activation of alternative pathways, and microenvironmental changes.
  • Understanding these resistance mechanisms is crucial for developing effective treatment strategies.

Conclusions:

  • Despite advances, resistance to FLT3 and IDH inhibitors poses a significant clinical challenge.
  • Further research into resistance mechanisms and combination therapies is essential to improve long-term patient outcomes.
  • Ongoing studies are exploring novel approaches to overcome resistance and enhance therapeutic efficacy.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K